A new blood test has been developed that could improve survival rates for pancreatic cancer, a disease frequently diagnosed at advanced stages.
Pancreatic cancer is the fifth leading cause of cancer deaths in the UK, with only 7 per cent of patients surviving five years or more after diagnosis.
Researchers at the University of Pennsylvania identified two new biomarkers, ANPEP and PIGR, which, when combined with two existing markers, significantly enhance detection.
The four-marker test successfully distinguished pancreatic cancer patients from non-cancer cases in 91.9 per cent of instances and identified early-stage cancer in 87.5 per cent of cases.
While promising, the retrospective study's findings require extensive further validation in larger, pre-diagnostic populations before the test can be implemented for screening high-risk individuals.
Bookmark popover
Removed from bookmarks